Data availability statement
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
References
1. Sanghai S, Wong C, Wang Z, et al. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study. J Am Heart Assoc . Mar 2020;9(6):e014108. doi:10.1161/JAHA.119.014108
2. Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. Pharm Pract (Granada) . 2019 Oct-Dec 2019;17(4):1709.
3. Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. Front Pharmacol . 2018;9:1220. doi:10.3389/fphar.2018.01220
4. Ezekowitz MD, Spahr J, Ghosh P, Corelli K. Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. J Interv Card Electrophysiol . Sep 2014;40(3):261-8. doi:10.1007/s10840-014-9893-z
5. Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW. Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits . Oct 2014;7(7):376-84.
6. Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother . Oct 2014;48(10):1258-68. doi:10.1177/1060028014540868
7. Kucey M, Bolt J, Albers L, Bell A, Iroh N, Toppings J. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis. Can J Hosp Pharm . 2016 Sep-Oct 2016;69(5):409-414.
8. Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral anticoagulants: appropriateness of prescribing in real-world setting.Intern Med J . Jul 2016;46(7):812-8. doi:10.1111/imj.13118
9. Steinberg BA, Shrader P, Thomas L, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol . Dec 2016;68(24):2597-2604. doi:10.1016/j.jacc.2016.09.966
10. Basaran O, Filiz Basaran N, Cekic EG, et al. PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study). Clin Appl Thromb Hemost . May 2017;23(4):384-391. doi:10.1177/1076029615614395
11. Howard M, Lipshutz A, Roess B, et al. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. J Thromb Thrombolysis . Feb 2017;43(2):149-156. doi:10.1007/s11239-016-1435-3
12. Shrestha S, Baser O, Kwong WJ. Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation. Ann Pharmacother . Aug 2017:1060028017728295. doi:10.1177/1060028017728295
13. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants.Int J Gen Med . 2017;10:87-94. doi:10.2147/IJGM.S129235
14. Jacobs MS, van Hulst M, Campmans Z, Tieleman RG. Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. Neth Heart J . Jul 2019;27(7-8):371-377. doi:10.1007/s12471-019-1267-9
15. Yu HT, Yang PS, Kim TH, et al. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.Stroke . 10 2018;49(10):2421-2429. doi:10.1161/STROKEAHA.118.021387
16. Shum P, Klammer G, Toews D, Barry A. Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. Can J Hosp Pharm . 2019 Nov-Dec 2019;72(6):428-434.
17. Jang BM, Lee OS, Shin EJ, et al. Factors related to inappropriate edoxaban use. J Clin Pharm Ther . Oct 2019;44(5):760-767. doi:10.1111/jcpt.12999
18. Angel Y, Zeltser D, Berliner S, et al. Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation. Br J Clin Pharmacol . 12 2019;85(12):2838-2847. doi:10.1111/bcp.14116
19. Antoniazzi S, Ardoino I, Proietti M, et al. Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial. Br J Clin Pharmacol . 09 2019;85(9):2134-2142. doi:10.1111/bcp.14029
20. Quintens C, De Rijdt T, Van Nieuwenhuyse T, et al. Development and implementation of ”Check of Medication Appropriateness” (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance. BMC Med Inform Decis Mak . 02 2019;19(1):29. doi:10.1186/s12911-019-0748-5
21. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants.Circ Cardiovasc Qual Outcomes . Mar 2016;9(2):182-5. doi:10.1161/CIRCOUTCOMES.115.002366
22. Uppuluri EM, McComb MN, Shapiro NL. Implementation of a Direct Oral Anticoagulation Screening Service at a Large Academic Medical Center Provided by a Pharmacist-managed Antithrombosis Clinic as a Method to Expand Antithrombotic Stewardship Efforts. J Pharm Pract . Jun 2020;33(3):271-275. doi:10.1177/0897190018799200
23. Boswell R, Bungard TJ. More than Just Chasing INRs: Patient-Centred Care in an Anticoagulation Clinic. Can J Hosp Pharm . 2015 May-Jun 2015;68(3):254-7. doi:10.4212/cjhp.v68i3.1460
24. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet . Mar 2014;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0
25. Cools F, Wollaert B, Vervoort G, et al. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.Acta Cardiol . Aug 2019;74(4):309-318. doi:10.1080/00015385.2018.1494089
26. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol . Jun 2017;69(23):2779-2790. doi:10.1016/j.jacc.2017.03.600
27. Bendayan M, Mardigyan V, Williamson D, et al. Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation.J Am Geriatr Soc . Jan 2021;doi:10.1111/jgs.16992
28. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.Stroke . 12 2018;49(12):2933-2944. doi:10.1161/STROKEAHA.118.020232
29. Chan YH, Lee HF, See LC, et al. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest . 09 2019;156(3):529-543. doi:10.1016/j.chest.2019.04.108
30. Van Ganse E, Danchin N, Mahé I, et al. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke . Jul 2020;51(7):2066-2075. doi:10.1161/STROKEAHA.120.028825
31. Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol . 2020;11:583311. doi:10.3389/fphar.2020.583311
32. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood . Aug 2014;124(6):955-62. doi:10.1182/blood-2014-03-563577
33. Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis . Sep 2017;11(9):243-256. doi:10.1177/1753944717714921
34. Miyazaki M, Matsuo K, Uchiyama M, et al. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci . 2020;6:2. doi:10.1186/s40780-020-0157-z
35. Yoshikawa A, Ramirez G, Smith ML, et al. Opioid Use and the Risk of Falls, Fall Injuries and Fractures among Older Adults: A Systematic Review and Meta-Analysis. J Gerontol A Biol Sci Med Sci . Feb 2020;doi:10.1093/gerona/glaa038
36. Seppala LJ, van de Glind EMM, Daams JG, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc . 04 2018;19(4):372.e1-372.e8. doi:10.1016/j.jamda.2017.12.099
37. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract . Jun 2010;64(7):956-67. doi:10.1111/j.1742-1241.2009.02286.x
38. Ashjian E, Kurtz B, Renner E, Yeshe R, Barnes GD. Evaluation of a pharmacist-led outpatient direct oral anticoagulant service. Am J Health Syst Pharm . Apr 2017;74(7):483-489. doi:10.2146/ajhp151026
39. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J . Nov 2012;33(21):2692-9. doi:10.1093/eurheartj/ehs071
40. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol . Apr 2015;65(13):1340-1360. doi:10.1016/j.jacc.2015.01.049
41. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace . 08 2018;20(8):1231-1242. doi:10.1093/europace/euy054
42. Dreijer AR, Kruip MJHA, Diepstraten J, et al. Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLoS One . 2020;15(6):e0235048. doi:10.1371/journal.pone.0235048